HealthDay News — More patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative breast cancer have been treated with neoadjuvant endocrine therapy (NET) due to COVID-19, according to a study presented at the annual meeting of the American Society of Breast Surgeons, held virtually from April 29 to May 2.

Lee G. Wilke, MD, from the University of Wisconsin School of Medicine and Public Health in Madison, and colleagues report on the initial impact of the COVID-19 pandemic on breast cancer using data for a COVID-19-specific registry, developed within the American Society of Breast Surgeons Mastery program. A total of 172 surgeons entered data on 2476 unique COVID-19 registry and 2303 Mastery registry patients between March 1 and October 28, 2020.

The researchers found that for patients with ER-positive, human epidermal growth factor receptor 2-negative disease, NET was used as a “usual” approach in 6.5% of patients in the COVID-19 registry, which was comparable to the 7.8% in the Mastery. In an additional 36% of patients, NET was used due to COVID-19. Patients were more likely to receive NET due to COVID-19 with increasing age and if they lived in the North or Southeast in a multinomial regression with surgery first/usual practice as the reference (odds ratios, 1.1, 2.2, and 1.6, respectively). Overall, 10.8% of patients had a change in surgical approach reported due to COVID-19, with the primary reasons being planned return for mastectomy or reconstruction (27 and 15%, respectively).

“COVID-related breast cancer treatment changes may have provided the context for testing new protocols, with some likely to persist beyond the pandemic,” Wilke said in a statement.


Continue Reading

Press Release

More Information